vertex presentation jp morgan, page-4

I agree. But could it be a question of funding priorities?

Do they accelerate a product in which they have two already commercialised, or do they accelerate other non-influenza products?

I want diversification.

If/when they hook up with a cash full american mergee, they can accelerate all their products. In the meantime,

I want BTA-798 front and centre.

I want RSV front and centre.

I want HCV front and centre (especially how this space seems to be going nuts at the moment).....